RNAi—siRNA and DsiRNA


This bibliography contains a list of research papers published by IDT scientists (bold). Click on the reference to read the PubMed abstract, or entire paper, if published in an open access journal. Otherwise, you will be able to obtain a PDF download of the paper through the PubMed site.

  1. Begin-Lavallee V, Midavaine E, Dansereau MA, Tetreault P, Longpre JM, Jacobi AM, Rose SD, Behlke MA, Beaudet N, Sarret P. (2016) Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development. Mol Pain, 12:1–16; PMID:27306408.
  2. Khan SM, Min A, Gora S, Houranieh GM, Campden R, Robitaille M, Trieu P, Petrin D, Jacobi AM, Behlke MA, Angers S, Hebert TE. (2015) G41 as a modulator of M3 muscarinic receptor signaling and novel roles of G1 subunits in the modulation of cellular signaling. Cell Signal, 27:1597–1608; PMID:25916507.
  3. Dudek H, Wong DH, Arvan R, Shah A, Wortham K, Ying B, Diwanji R, Zhou W, Holmes B, Yang H, Cyr WA, Zhou Y, Shah A, Farkiwala R, Lee M, Li Y, Rettig GR, Collingwood MA, Basu SK, Behlke MA, Brown BD. (2014) Knockdown of β-catenin with Dicer-substrate siRNAs reduces liver tumor burden in vivo. Mol Ther, 22:92–101. PMID: 24089139.
  4. Khairuddin N, Blake SJ, Firdaus F, Steptoe RJ, Behlke MA, Hertzog PJ, McMillan NA. (2014) In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours. Immunol Cell Biol, 92(2):156–163.
  5. Krishnamurthy S, Behlke MA, Apicella MA, McCray PB, Davidson BL. (2014) Platelet activating factor receptor activation improves siRNA uptake and RNAi responses in well-differentiated airway epithelia. Molec Therapy Nucl Acids, 3 e175:PMID:25025465.

  6. Rose S, Behlke MD. (2013) Synthetic Dicer-Substrate siRNAs as Triggers of RNA Interference. In: Howard KA (editor) RNA Interference from Biology to Therapeutics: Advances in Delivery Science and Technology: Springer US, :31–56.
  7. Fernandez G, Zaikos TD, Khan SZ, Jacobi AM, Behlke MA, Zeichner SL. (2013) Targeting Iκβ proteins for HIV latency activation: the role of individual Iκβ and NF-κβ proteins. J Virol, 87(7):3968–3978.
  8. Keiser MS, Geoghegan JC, Boudreau RL, Lennox KA, Davidson BL. (2013) RNAi or overexpression: alternative therapies for spinocerebellar ataxia type 1. Nuerobiol Dis, 56C:6–13.
  9. Ramachandran S, Krishnamurthy S, Jacobi AM, Wohlford-Lenane C, Behlke MA, Davidson BL, and McCray PB. (2013) Efficient delivery of RNA-interference oligonucleotides to polarized airway epithelia in vitro. Am J Physiol Lung Cell Mol Physiol, 305:L23-32.
  10. Tetreault P, Beaudet N, Perron A, Belleville K, Rene A, Cavelier F, Martinez J, Stroh T, Jacobi AM, Rose SD, Behlke MA, and Sarret P. (2013) Spinal NTS2 receptor activation reverses signs of neuropathic pain. FASEB J, 27:3741-3752.
  11. Rettig GR, Behlke MA. (2012) Progress towards in vivo use of siRNAs - II. Mol Ther, 20(3):483–512.
  12. Dallas A, Ge Q, Ilves H, Kumar P, Shorenstein J, Kazakov SA, Cuellar TL, McManus MT, Behlke MA, Johnston BH . (2012) Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing. Nucleic Acids Res, 40(18):9255–9271.
  13. Gantier MP, Stunden HJ, McCoy CE, Behlke MA, et al. (2012) A miR-19 regulon that controls NF-kB signaling. Nucleic Acids Res, 40(16):8048–8058.
    miRNA antagonists (AMOs) to selected miR-19 family members  and Dicer-substrate siRNAs (DsiRNAs) targeting RNF11 and EGFP (target and control, respectively) are used in a study to show that targeting miR-19 and linked family members may regulate NF-kappaB signalling in inflammation.
  14. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA. (2012) SiRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol, 90(2):187–196.
  15. Kim N, Jiang D, Jacobi AM, Lennox KA, Rose SD, Behlke MA, Salem AK. (2012) Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA. Int J Pharm, 427(1):123–133.
  16. Krishnamurthy S, Behlke MA, Ramachandran S, Salem AK,McCray PB Jr, Davidson BL. (2012) Manipulation of Cell Physiology Enables Gene Silencing in Well-differentiated Airway Epithelia. Mol Ther Nucl Acids, 1:e41.
  17. Lundberg P, Yang H-J, Jung S-J, Behlke MA, Rose SD, Cantin EM. (2012) Protection against TNFα-dependent liver toxicity by intraperitoneal liposome delivered Dting TNFα in vivo siRNA target. J Control Release, 160(2):194-199.
  18. Walk RM, Elliot ST, Blanco FC, Snyder JA, Jacobi AM, Rose SD, Behlke MA, Salem AK, Vukmanovic S, Sandler AD. (2012) T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor- stimulated macrophages. ImmunoTargets and Therapy, 1:13–23.
    Use of Dicer-substrate siRNAs (DsiRNAs) for effective in vitro and in vivo suppression of IL-10 cytokine in primary bone marrow macrophages and A/J mice, respectively.
  19. Weinstein S, Emmanuel R, Jacobi AM, Abraham A, Behlke MA, Sprague AG, Novobrantseva T, Nagler, A, Peer D. (2012) RNA inhibition highlights Cyclin D1 as a potential therapeutic target for Mantle Cell Lymphoma. PLoS ONE, 7:e43343.
  20. Zhou J, Song M-S, Jacobi AM, Behlke MA, Wu X, Rossi JJ. (2012) Deep sequencing analyses of DsiRNAs reveal the influence of 3’ terminal overhangs on dicing polarity, strand selectivity and RNA editing of siRNAs. Mol Therapy Nucleic Acids, 1:e17.
  21. Ge Q, Dallas A, Ilves H, Shorenstein J, Behlke MA, Johnston BH. (2010) Effects of chemical modifications on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA, 16(1):118–130.
  22. Nawroth I, Alsner J, Behlke MA, Besenbacher F, Overgaard J, Howard KA, Kjems J. (2010) Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNF prevents radiation-induced fibrosis. Radiother Oncol, 97(1):143–148.
  23. Sakurai K, Amarzguioui M, Kim DH, Alluin J, Heale B, Song MS, Gatignol A, Behlke MA, Rossi JJ. (2010) A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res, 39(4):1510–1525.
  24. Devor EJ, Huang L, Abdukarimov A, Abdurakhmonov IY. (2009) Methodologies for in vitro cloning of small RNAs and applications for plant genomics. Int J Plant Genomics, :e915061.
  25. McQuisten KA, Peek AS. (2009) Comparing artificial neural networks, general linear models and support vector machines in building predictive models for small interfering RNAs. PLoS One, 4(10):e7522.
  26. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. (2009) Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model . Mol Ther, 17(1):162–168.
    DsiRNAs targeting TNF-α, administered intraperitoneally using chitosan nanoparticles, reduce inflammation in murine collagen-induced arthritis.
  27. LaCroix-Fralish ML, Mo G, Smith SB, Sotocinal SG, Ritchie J, Austin JS, Melmed K, Schorscher-Petcu A, Laferriere AC, Lee TH, Romanovsky D, Liao G, Behlke MA, Clark DJ, Peltz G, Séguéla P, Dobretsov M, Mogil JS. (2009) The β 3 subunit of the Na+,K+-ATPase mediates variable nociceptive sensitivity in the formalin test. Pain, 144(3):294–302.
  28. Manzel LJ, Chin CL, Behlke MA, Look DC. (2009) Regulation of bacteria-induced intercellular adhesion molecule-1 by CCAAT/enhancer binding proteins. Am J Respir Cell Mol Biol, 40(2):200–210.
  29. Behlke MA. (2008) Chemical modification of siRNAs for in vivo use. Oligonucleotides, 18(4):305–320.
  30. Collingwood MA, Rose SD, Huang L, Hillier C, Amarzguioui M, Wiiger MT, Soifer HS, Rossi JJ, Behlke MA. (2008) Chemical modification patterns compatible with high potency Dicer-substrate small interfering RNAs. Oligonucleotides, 18(2):187–200.
  31. Doré-Savard L, Roussy G, Dansereau MA, Collingwood MA, Lennox KA, Rose SD, Beaudet N, Behlke MA, Sarret P. (2008) Central delivery of Dicer-substrate siRNA: a direct application for pain research. Mol Ther, 16(7):1331–1339.
  32. Hefner E, Clark K, Whitman C, Behlke MA, Rose SD, Peek AS, Rubio T. (2008) Increased potency and longevity of gene silencing using validated Dicer substrates. J Biomol Tech, 19(4):231–237.
  33. Hildebrand MS, Newton SS, Gubbels SP, Sheffield AM, Kochhar A, de Silva MG, Dahl HH, Rose SD, Behlke MA, Smith RJ. (2008) Advances in Molecular and Cellular Therapies for Hearing Loss. Mol Ther, 16(2):224–236.
  34. Kim DH, Behlke M, Rossi JJ. (2008) Designing and utilization of siRNAs targeting RNA binding proteins. Methods Mol Biol, 488:367–381.
  35. Soifer HS, Sano M, Sakurai K, Chomchan P, Saetrom P, Sherman MA, Collingwood MA, Behlke MA, Rossi JJ. (2008) A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs . Nucleic Acids Res, 36(20):6511–6522.
  36. Peek AS, Behlke MA. (2007) Design of active small interfering RNAs. Curr Opin Mol Ther, 9(2):110–118.
  37. Peek AS. (2007) Improving model predictions for RNA interference activities that use support vector machine regression by combining and filtering features . BMC Bioinformatics, 8:e182.
  38. Behlke MA. (2006) Progress towards in vivo use of siRNAs. Mol Ther, 13(4):644–670.
  39. Rose SD, Collingwood MA, Behlke MA. (2006) Optimizing knockdown of gene expression using the TriFECTa Dicer-substrate RNAi reagent system. Nature Methods, 3:v–vii.
  40. Amarzguioui M, Lundberg P, Cantin E, Hagstrom J, Behlke MA, Rossi JJ. (2006) Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc, 1(2):508–517.
  41. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. (2006) Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon transduction. Virology, 344(2):328–339.
  42. Rose SD, Kim D-H, Amarzguioui M, Heidel JD, Collingwood MA, Davis ME, Rossi JJ, Behlke MA. (2005) Functional polarity is introduced by Dicer processing of short substrate RNAs. J Biomol Tech, 33(13):4140–4156.
  43. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. (2005) Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol, 23(2):222–226.
  44. Soifer HS, Zaragoza A, Peyvan M, Behlke MA, Rossi JJ. (2005) A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res, 33(3):846–856.